相关实验视频
Updated: Sep 12, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.2K
对于昂贵的口服分子向剂的低通用药物透率:在日本使用通用伊马替尼的经验
Keisuke Kidoguchi1, Hiroshi Ureshino1, Shinya Kimura1
1Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan.
Internal medicine (Tokyo, Japan)
|August 6, 2025
概括
尽管成本较低,但通用伊马替尼在日本仍未得到充分利用. 由于保险系统,Gleevec® 保持了市场主导地位,这促使对品牌名称偏好的新费用.
科学领域:
- 卫生经济学 卫生经济学
- 药品市场分析 药品市场分析
- 瘤学 药物使用 药物使用
背景情况:
- 通用伊马替尼布已有超过10年的历史,但在日本仍未得到充分利用.
- 格利维克 (imatinib mesylate) 历来主导了日本市场的这种药物.
研究的目的:
- 为了调查日本的伊马替尼布市场趋势.
- 探索为什么人们继续偏爱品牌Gleevec®而不是通用药的原因.
主要方法:
- 对公开可用的医疗保健成本和仿制药销售数据的分析.
- 包括来自OHARA制药有限公司的专有市场份额数据.
- 基于卫生,劳动和福利部 (MHLW) 预测的成本削减模拟.
主要成果:
- 通用伊马替尼布于2014年推出,价格显著降低 (50-55%的Gleevec®).
- 在2022财年,Gleevec®保持了72%的市场份额,这得益于日本的全民医疗保险和补偿系统.
- 选择性治疗费 (SENTEI RYOYOHI) 于2024年10月实施,要求患者支付部分成本差异,以选择Gleevec®而不是仿制药.
结论:
- 选择性护理系统旨在减轻品牌伊马替尼的患者成本增加,并保护日本的医疗保健系统.
- 个人医疗费用与国家医疗保健支出之间的平衡至关重要.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Prescription, Nonprescription and Orphan Drugs
846
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
846
Mitogens and the Cell Cycle
6.8K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.8K

